After flying under the radar for the last three years, Vium Inc. is coming out of the shadows with a technology it thinks will change the face of in vivo testing. By bringing high tech...
Additional data from the double-blind, European Phase III Study 17 trial in 360 patients showed that 2 mg/cm 2 ATX-101 significantly improved mean CR-SMFRS score, a co-primary endpoint, by 0.77 points from baseline to week...
After flying under the radar for the last three years, Vium Inc. is coming out of the shadows with a technology it thinks will change the face of in vivo testing. By bringing high tech...
Additional data from the double-blind, European Phase III Study 17 trial in 360 patients showed that 2 mg/cm 2 ATX-101 significantly improved mean CR-SMFRS score, a co-primary endpoint, by 0.77 points from baseline to week...